Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450847 | 0.90 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL14777188 | 0.87 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2453501 | 0.85 | GUCY1A1 (0.51) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL14776795 | 0.85 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL14777025 | 0.82 | GUCY1A1 (0.51) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL14776815 | 0.81 | GUCY1A1 (0.50) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2452838 | 0.80 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL2455829 | 0.79 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2452848 | 0.78 | GUCY1A1 (0.45) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL2453286 | 0.78 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1KCNH2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | claimed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | claimed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, GUCY1A2, PDE3A | GUCY1A1 5/4885GUCY1B1 8/4885KCNH2 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.